I agree that this site is using cookies. You can find further informations here.
X
Naomi Michels
13  results:
Search for persons X
?
1

Targeted treatment options for paediatric B-cell precursor ..:

Michels, Naomi ; Hormann, Femke M. ; Boeree, Aurélie...
EJC Paediatric Oncology.  3 (2024)  - p. 100140 , 2024
Link: https://doi.org/10.1016/..
 
?
2

Inotuzumab ozogamicin as single agent in pediatric patients..:

Pennesi, Edoardo ; Michels, Naomi ; Brivio, Erica...
Leukemia.  36 (2022)  6 - p. 1516-1524 , 2022
Link: https://doi.org/10.1038/..
 
?
3

Minimal residual disease, long-term outcome, and IKZF1 dele..:

Michels, Naomi ; Boer, Judith M ; Enshaei, Amir...
The Lancet Haematology.  8 (2021)  10 - p. e700-e710 , 2021
Link: https://doi.org/10.1016/..
 
?
4

Targeted treatment options for paediatric B-cell precursor ..:

Naomi Michels ; Femke M. Hormann ; Aurélie Boeree...
http://www.sciencedirect.com/science/article/pii/S2772610X23001381.  , 2024
Link: https://doi.org/10.1016/..
 
?
5

Inotuzumab ozogamicin as single agent in pediatric patients..:

Pennesi, Edoardo ; Michels, Naomi ; Brivio, Erica...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9162924/.  , 2022
Link: http://www.ncbi.nlm.nih...
 
?
6

Minimal residual disease, long-term outcome, and IKZF1 dele..:

Michels, Naomi ; Boer, Judith M ; Enshaei, Amir...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8480280/.  , 2021
Link: http://www.ncbi.nlm.nih...
 
?
7

Minimal residual disease, long-term outcome, and IKZF1 dele..:

Michels, Naomi ; Boer, Judith M ; Enshaei, Amir...
Michels , N , Boer , J M , Enshaei , A , Sutton , R , Heyman , M , Ebert , S , Fiocco , M , de Groot-Kruseman , H A , van der Velden , V H J , Barbany , G , Escherich , G , Vora , A , Trahair , T , Dalla-Pozza , L , Pieters , R , zur Stadt , U , Schmiegelow , K , Moorman , A V , Zwaan , C M & den Boer , M L 2021 , ' Minimal residual disease, long-term outcome, and IKZF1 deletions in children and adolescents with Down syndrome and acute lymphocytic leukaemia : a matched cohort study ' , The Lancet Haematology , vol. 8 , no. 10 , pp. E700-E710 . https://doi.org/10.1016/S2352-3026(21)00272-6.  , 2021
Link: https://pure.eur.nl/en/p..
 
?
8

Minimal residual disease, long-term outcome, and IKZF1 dele..:

N. (Naomi) Michels ; Judith M. Boer ; Amir Enshaei...
http://repub.eur.nl/pub/136812.  , 2021
Link: http://repub.eur.nl/pub/..
 
?
9

Elimination of charge-carrier trapping by molecular design:

Sachnik, Oskar ; Tan, Xiao ; Dou, Dehai...
Nature Materials.  22 (2023)  9 - p. 1114-1120 , 2023
Link: https://doi.org/10.1038/..
 
?
10
Abarca-Gómez, Leandra ; Abdeen, Ziad A. ; Hamid, Zargar Abdul.... (2017)  10113 - p. 2627-2642
Link: http://dx.doi.org/10.101..
 
?
11

Tumours with class 3 BRAF mutants are sensitive to the inhi..:

Yao, Zhan ; Yaeger, Rona ; Rodrik-Outmezguine, Vanessa S....
Nature.  548 (2017)  7666 - p. 234-238 , 2017
Link: https://doi.org/10.1038/..
 
?
12

Procalcitonin for diagnosis of bacterial pneumonia in criti..:

Pfister, Roman ; Kochanek, Matthias ; Leygeber, Timo...
Critical Care.  18 (2014)  2 - p. R44 , 2014
Link: https://doi.org/10.1186/..
 
?
13

Elimination of charge-carrier trapping by molecular design:

Sachnik, Oskar ; Tan, Xiao ; Dou, Dehai...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10465354/.  , 2023
Link: http://www.ncbi.nlm.nih...
 
1-13